Latest News from "The Pink Sheet" DAILY - Salix's Xifaxan Advisory Panel Review

Salix's Xifaxan Draws Ambivalent Recommendation From Advisory Panel

Salix's Xifaxan for hepatic encephalopathy passed advisory committee review, but members expressed unease about lingering safety concerns and called for additional studies. read_more_>

 

Pfizer, Lilly And Merck Strike Up Cancer Research Partnership In Asia

The not-for-profit Asian Cancer Research Group will focus initially on identifying biomarkers for lung and gastric cancers. read_more_>

 

CMS Proposes "Trial Sizes" Of Prescriptions To Curb Waste Of Unused Drugs In Part D

Under a plan outlined in a draft Medicare Part D "call letter," patients receiving a new prescription for a drug previously unused by them would be able to receive an initial trial size supply of no more than seven to 14 days. read_more_>

 

No Drama Dendreon: Anticipated Provenge Launch Appears On Track

The biotech says it will launch prostate cancer vaccine the day after approval. read_more_>

Second Time Around: Cephalon Buys Ception Based On Cinquil Data In Asthma

Cephalon passed on a first option to buy Ception Therapeutics, but will now acquire the company for $250 million following encouraging Phase II results. read_more_>

Healthiness Of Actors In DTC Spots Returns As Issue As FDA Cites Aricept Ads

Pfizer, which co-markets the Alzheimer's treatment with Eisai, could feel the biggest impact of the notice of violation due to its settlement with state attorneys general. read_more_>

 

DoJ Sets Its Sights On DESI Drugs: Eon Labs Settles Claims It Marketed An Ineffective Drug

Novartis subsidiary agrees to pay $3.5 million to settle claims it illegally sought government reimbursement for Nitroglycerin SR after FDA found it to be less than effective. read_more_>

"The Pink Sheet" DAILY - Daily, in-depth analysis of the key developments shaping the biopharma industry. Not a subscriber? To register for a free trial, click here